Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer

• Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refract...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, John K., Lakomy, David S., McDonald, Yassmina, Kapp, Daniel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292902/
https://www.ncbi.nlm.nih.gov/pubmed/32551353
http://dx.doi.org/10.1016/j.gore.2020.100581
Descripción
Sumario:• Recurrent resistant uterine cancer patients have a poor prognosis with limited treatment options. • Pembrolizumab is a PD1-inhibitor that was recently FDA approved for MMR-deficient solid tumors, including uterine cancer. • Pembrolizumab can produce long-term durable response in resistant, refractory endometrial cancer with minimal side effects.

Ejemplares similares